Co-Chair
Renata Fialho

Co-Chair
Anne Walsh

Healthcare and Life Sciences Law Committee

The Healthcare and Life Sciences Law Committee addresses legal issues in the healthcare and life sciences sectors, such as medicine, intellectual property, biotech, bioethics, regulatory matters, and scientific developments. With a dynamic, diverse, and growing membership, the Committee fosters collaboration to tackle industry challenges, such as increased competition and regulatory changes.

We provide a platform for discussion, sharing knowledge, and updating members on key developments. Through conferences, seminars, and global events, the Committee promotes professional growth, enabling members to benefit from advanced practices in well-established jurisdictions while supporting those new to this field.

Forthcoming conferences and webinars View All Conferences

Publications

The right to be forgotten in Portugal: health and insurance law considerations

The right to be forgotten plays a crucial role in both insurance law and health law, particularly when addressing sensitive health-related information. This article discusses how health data intersects with insurance law, and the recent developments in Portugal in relation to the right to be forgotten for people who have overcome or mitigated situations of aggravated risk of health or disability.

Released on Feb 11, 2025

The legal framework for partnerships for productive development: PDPs and PDILs

This article analyses recent regulatory changes in Brazil’s health economic-industrial complex, including the transition from Decree 9,245/2017 to Decree 11,715/2023 and the impact of Ordinances 4,472/2024 and 4,473/2024. While these changes aim to enhance oversight, foster innovation and stimulate local production, they have also introduced regulatory uncertainty.

Released on Feb 11, 2025

Conflicts of interest in the relationship between medical professionals and the pharmaceutical industry

This article explores the regulatory gaps in Brazil concerning the relationship between medical professionals and the pharmaceutical industry, focusing on ethical and conflict of interest concerns. It analyses national and state-level measures, including the Minas Gerais ‘Sunshine Act’ and CFM Resolution No 2,386/2024 – discussing their implications, challenges and alignment with global transparency initiatives to safeguard patient care and uphold healthcare integrity.

Released on Feb 11, 2025

Brazil: access and reimbursement of medicines in the public market

This article intends to briefly describe: how the Brazilian legislative framework regulates the incorporation of new pharmaceutical products into the Brazilian public healthcare system (Sistema Único de Saúde or SUS), commonly known as ‘reimbursement’ in other international jurisdictions; which public authorities are involved; what the ‘judicialisation’ phenomenon is; and the importance of strategic legal support throughout the process of incorporation.

Released on Feb 11, 2025

Projects

IBA Healthcare and Life Sciences Law Committee annual global surveys

Each year the Healthcare and Life Sciences Law Committee has produced a new comparative legal guide covering a highly relevant topic in over 50 countries. This guide is intended to offer practitioners and industry users easy access to the relevant applicable rules. In 2023, the Committee addressed questions related to telemedicine. In 2024, the Committee summarised the requirements for promoting pharmaceutical and medical devices in these countries.


Join us on LinkedIn

If you are a member of the Healthcare and Life Sciences Law Committee, for additional networking opportunities, programs, interviews with fellow members and tips all exclusive to members, join our LinkedIn page at: https://www.linkedin.com/groups/9166617/.